SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is generating significant community buzz, driven by rumors of major new exchange listings, increased trading volume, and its recent tokenomics updates including a burn proposal. The crypto community is highly engaged, highlighting its AI-integrated and cross-chain bridging technology, and speculating on substantial "altseason" gains due to its perceived undervaluation and low market capitalization as a liquid staking protocol.

Polygon

Polygon is experiencing a surge in conversation fueled by strong market momentum and its ongoing Open Money Stack Initiative, alongside reports of significant on-chain revenue growth and strategic token burning. The community is actively discussing Polygon's perceived undervaluation and its pivotal role as a scalable Layer 2 solution for Ethereum, anticipating its potential to dominate the payments sector amidst growing institutional interest and debates around its token's branding.

Willow Lane Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 3, 2024 and is headquartered in New York, NY.

Willow Lane Acquisition Corp. - Ordinary Shares - Class A

Willow Lane Acquisition Corp. is trending as the community anticipates its merger with Boost Run, an AI infrastructure company widely considered an undervalued "sleeping giant" in a high-demand sector. Investors are actively discussing the imminent S-4 filing as the next catalyst, drawing comparisons to successful AI infrastructure plays and expecting a significant run in the burgeoning data center market.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is drawing significant attention as its community debates its immediate future, with some anticipating major "altseason" gains fueled by ongoing technical breakouts and rumors of potential new exchange listings. Proponents emphasize its core utility as fast, low-fee digital money and the transformative potential of upcoming protocol upgrades like LitVM. However, a strong contingent remains highly skeptical, labeling it a "dead coin" amid broader crypto market volatility.

The White Whale

WHITEWHALE CRYPTO is generating buzz for its rapid market cap expansion and a recent exchange listing, fueling significant community discussion. Enthusiastic holders point to its unique tokenomics, where locked liquidity and a specific buyer-seller dynamic are believed to drive value for floating tokens, likening its potential to other meme coin successes. Meanwhile, a subset of the community remains cautious, debating its long-term viability and whether current activity is indicative of a pump and dump.

What is Mars Protocol?  Mars Protocol consists of a money market, called Red Bank, and a generalized credit primitive called Rover. Mars Protocol utilizes a so-called hub and outpost topology, whereby its base, Mars Hub acts as a command center for numerous outposts. Each outpost consists of an instance of Red Bank and Rover and the first of many outposts will be the Osmosis chain.

Mars

MARS CRYPTO is trending due to community excitement surrounding a nascent meme token, with users speculating on its potential for rapid growth and drawing parallels to other popular meme coins. While some discussion also involves an upcoming space technology ETF sharing the $MARS ticker, the current speculative interest largely centers on the cryptocurrency.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending amidst significant community enthusiasm for its "Airlock" initiative, which has seen over 35% of its supply locked, signaling strong conviction and reduced selling pressure. The community is actively discussing this unique supply control mechanism, its USD1-paired liquidity pool, and recent celebrity endorsement as key drivers in the meme coin sector.

Constellation Software Inc

Constellation Software is trending as investors assess its robust Q3 results, which reported strong revenue and free cash flow growth amidst a significant share price pullback. The community is actively debating whether this represents a rare buying opportunity due to perceived undervaluation and solid fundamentals, while also considering potential impacts from AI on its niche software empire. Analysts largely maintain bullish outlooks, highlighting the company's proven acquisition strategy and stable leadership.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

The biotech sector, reflected in LABU's performance, continues to capture market attention amid accelerating advancements in AI-driven drug discovery and expectations of accommodative monetary policy. The community is actively debating the sustainability of this strong upward trend, with many anticipating further sector growth and a rotation of capital into biotech innovation. Discussions highlight the transformative impact of artificial intelligence on pharmaceutical research and development, contrasting the sector's momentum against broader market concerns.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE is gaining significant attention as its underlying Hyperliquid decentralized exchange demonstrates surging trading volumes and record open interest. The community is highly bullish, emphasizing its robust deflationary tokenomics with substantial buybacks and a growing ecosystem including new stablecoin integrations and institutional treasury adoption. Many view HYPE as a top contender disrupting the DeFi derivatives market, poised for continued growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

Equity

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's Why...

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% - Time to Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3% - Time to Sell...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Hold" by Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen research firms that are covering the stock, MarketBeat reports. Three...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.7% - Should You Sell?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 7.7% - Time to Sell...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 6% - Still a Buy?

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 6% - Here's Why...

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of...

MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit MLTX Deadline: MLTX Investors with Losses in Excess of $100K...

MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX MLTX DEADLINE: Faruqi & Faruqi Reminds...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

MoonLake Immunotherapeutics

Traders are buzzing with intense speculation about a potential acquisition, frequently citing previous Merck offers and anticipating new bids ranging from $60 to $95 per share.

The stock is surging following positive FDA feedback, indicating that existing trial data for sonelokimab in HS is sufficient for a Biologics License Application, de-risking the path to approval.

Aggressive buying volume and analyst upgrades are putting pressure on a significant short interest (around 13.73% of float), with many expecting a major short squeeze to propel prices higher.

Following recent positive news, analysts are significantly raising price targets, with some retail investors now eyeing immediate gains to $20-$30 next week and beyond.

Recent SEC Form 4 filings showing significant equity grants to top executives have sparked debate, with some interpreting them as a highly bullish sign for future events.

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MLTX News

MLTXMoonLake Immunotherapeutics